Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade.
Saved in:
| Title: | Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade. |
|---|---|
| Authors: | Hsu J; Department of Molecular and Cell Biology, Immunotherapy and Vaccine Research Initiative, Cancer Research Laboratory, Division of Immunology and Pathogenesis, University of California, Berkeley, Berkeley, California, USA., Hodgins JJ; Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, Ontario, Canada.; Centre for Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada., Marathe M; Department of Molecular and Cell Biology, Immunotherapy and Vaccine Research Initiative, Cancer Research Laboratory, Division of Immunology and Pathogenesis, University of California, Berkeley, Berkeley, California, USA., Nicolai CJ; Department of Molecular and Cell Biology, Immunotherapy and Vaccine Research Initiative, Cancer Research Laboratory, Division of Immunology and Pathogenesis, University of California, Berkeley, Berkeley, California, USA., Bourgeois-Daigneault MC; Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, Ontario, Canada.; Centre for Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada., Trevino TN; Department of Molecular and Cell Biology, Immunotherapy and Vaccine Research Initiative, Cancer Research Laboratory, Division of Immunology and Pathogenesis, University of California, Berkeley, Berkeley, California, USA., Azimi CS; Department of Molecular and Cell Biology, Immunotherapy and Vaccine Research Initiative, Cancer Research Laboratory, Division of Immunology and Pathogenesis, University of California, Berkeley, Berkeley, California, USA., Scheer AK; Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, Ontario, Canada.; Centre for Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada., Randolph HE; Department of Molecular and Cell Biology, Immunotherapy and Vaccine Research Initiative, Cancer Research Laboratory, Division of Immunology and Pathogenesis, University of California, Berkeley, Berkeley, California, USA., Thompson TW; Department of Molecular and Cell Biology, Immunotherapy and Vaccine Research Initiative, Cancer Research Laboratory, Division of Immunology and Pathogenesis, University of California, Berkeley, Berkeley, California, USA., Zhang L; Department of Molecular and Cell Biology, Immunotherapy and Vaccine Research Initiative, Cancer Research Laboratory, Division of Immunology and Pathogenesis, University of California, Berkeley, Berkeley, California, USA., Iannello A; Department of Molecular and Cell Biology, Immunotherapy and Vaccine Research Initiative, Cancer Research Laboratory, Division of Immunology and Pathogenesis, University of California, Berkeley, Berkeley, California, USA., Mathur N; Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, Ontario, Canada.; Centre for Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada., Jardine KE; Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, Ontario, Canada.; Centre for Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada., Kirn GA; Department of Molecular and Cell Biology, Immunotherapy and Vaccine Research Initiative, Cancer Research Laboratory, Division of Immunology and Pathogenesis, University of California, Berkeley, Berkeley, California, USA., Bell JC; Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, Ontario, Canada.; Centre for Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada., McBurney MW; Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, Ontario, Canada.; Centre for Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada., Raulet DH; Department of Molecular and Cell Biology, Immunotherapy and Vaccine Research Initiative, Cancer Research Laboratory, Division of Immunology and Pathogenesis, University of California, Berkeley, Berkeley, California, USA., Ardolino M; Department of Molecular and Cell Biology, Immunotherapy and Vaccine Research Initiative, Cancer Research Laboratory, Division of Immunology and Pathogenesis, University of California, Berkeley, Berkeley, California, USA.; Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, Ontario, Canada.; Centre for Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada. |
| Source: | The Journal of clinical investigation [J Clin Invest] 2018 Oct 01; Vol. 128 (10), pp. 4654-4668. Date of Electronic Publication: 2018 Sep 10. |
| Publication Type: | Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: American Society for Clinical Investigation Country of Publication: United States NLM ID: 7802877 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1558-8238 (Electronic) Linking ISSN: 00219738 NLM ISO Abbreviation: J Clin Invest Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
